Evidence map›Paper›PMID 25716637›Full record

Trial reportEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2015

EFFECT OF HIGH-DOSE VITAMIN D REPLETION ON GLYCEMIC CONTROL IN AFRICAN-AMERICAN MALES WITH PREDIABETES AND HYPOVITAMINOSIS D.

Elena Barengolts, Buvana Manickam, Yuval Eisenberg, Arfana Akbar, Subhash Kukreja, Irina Ciubotaru

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01375660 (Vitamin D Deficiency and Treatment in Male Veterans at Risk for Diabetes), which is not on this map. Cited by 28 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 4 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01375660 nacompletednot on this map

Vitamin D Deficiency and Treatment in Male Veterans at Risk for Diabetes

TypeinterventionalSponsorUS Department of Veterans AffairsRan2011 to 2014Enrolled205ConditionsImpaired Fasting Glucose, Impaired Glucose Tolerance, Vitamin D InsufficiencyArmsPlacebo, 50K vitamin D2
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis.American journal of preventive medicine · 2022 · on this map
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Article
  13. Review
  14. Vitamin D efficacy in type 1 and type 2 diabetes.Journal of bone and mineral metabolism · 2024
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Vitamin D Supplementation for Prevention of Type 2 Diabetes Mellitus: To D or Not to D?The Journal of clinical endocrinology and metabolism · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Elena Barengolts
Buvana Manickam
Yuval Eisenberg
Arfana Akbar
Subhash Kukreja
Irina Ciubotaru
University of Illinois Chicago · USJesse Brown VA Medical Center · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR029879 · NCRR · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MAZZONE, THEODORE · 2009 to 2011
$11.0M
Intramural VA VA999999NCRR NIH HHS UL1 RR029879
6 · The paper itself

Abstract

objectiveThis double-blind, randomized, controlled trial evaluated whether 12 months of high-dose vitamin D2 supplementation improved insulin sensitivity and secretion and glycemic status.

methodsAfrican-American males (AAM) with prediabetes (glycosylated hemoglobin [A1C] 5.7-6.4%), hypovitaminosis D (25-hydroxyvitamin D [25OHD] 5-29 ng/mL), and prevalent medical problems were supplemented with vitamin D3 (400 IU/day) and then randomized to weekly placebo or vitamin D2 (50,000 IU). The primary outcome was the change in oral glucose insulin sensitivity (OGIS, from an oral glucose tolerance test [OGTT]) after 12 months of treatment. Secondary outcomes included other glycemic indices, A1C, and incident diabetes.

resultsBaseline characteristics were similar in vitamin D-supplemented (n = 87) and placebo (n = 86) subjects completing the trial with average concentrations 14.4 ng/mL, 362 mL × min(-1) × m(-2), and 6.1% for 25OHD, OGIS and A1C, respectively. After 12 months, the vitamin D-supplemented group had a change in serum 25OHD +35 versus +6 ng/mL for placebo, P<.001; OGIS +7.8 versus -16.0 mL × min(-1) × m(-2) for placebo, P = .026; and A1C -0.01 versus +0.01% for placebo, P = .66. Ten percent of subjects in both groups progressed to diabetes. A posthoc analysis of participants with baseline impaired fasting glucose (IFG) showed that more subjects in the vitamin D subgroup (31.6%) than placebo (8.3%) returned to normal glucose tolerance, but the difference did not reach significance (P = .13).

conclusionThe trial does not provide evidence that 12 months of high-dose D2 repletion improves clinically relevant glycemic outcomes in subjects with prediabetes and hypovitaminosis D (NCT01375660).

Indexed as

AgedBlack or African AmericanBlood GlucoseDietary SupplementsDouble-Blind MethodErgocalciferolsGlycated HemoglobinHumansMaleMiddle AgedPrediabetic StateVitamin DVitamin D Deficiency25-hydroxyvitamin DBlood GlucoseErgocalciferolsGlycated Hemoglobinhemoglobin A1c protein, humanVitamin D

Identifiers

PMID25716637
PMCPMC4916973
OpenAlexW2073587705

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.